Trevi Therapeutics stock soars to 52-week high of $4.68

Trevi Therapeutics, Inc. (NASDAQ:TRVI) stock has reached a notable milestone, hitting a 52-week high of $4.68. According to InvestingPro data, the company maintains strong financial health with a current ratio of 7.38, indicating robust liquidity. However, analysis suggests the stock is currently trading above its Fair Value. This peak reflects a significant uptrend for the biopharmaceutical company, which specializes in developing treatments for serious neurological and neuroimmune disorders. Over the past year, Trevi Therapeutics has seen an impressive 66.79% increase in its stock value, with analyst price targets ranging from $7 to $21. The company’s $403.49M market capitalization and strong momentum have caught analysts’ attention, with two analysts recently revising earnings estimates upward. The 52-week high represents a key indicator of the company’s current market performance and sets a new benchmark for its stock valuation. Discover 12 additional exclusive insights about TRVI with InvestingPro’s comprehensive research report.

In other recent news, Travere Therapeutics announced its plan to submit a supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) by the end of the first quarter of 2025, following a Type C meeting with the FDA. This submission is based on data from the Phase 3 DUPLEX and Phase 2 DUET studies, aiming to treat focal segmental glomerulosclerosis (FSGS), a rare kidney disorder. If approved, FILSPARI could become the first medicine indicated for FSGS, which affects over 40,000 individuals in the U.S. Meanwhile, Trevi Therapeutics has seen significant developments, with B.Riley analyst Mayank Mamtani raising the price target for Trevi to $11.00 from $6.00, maintaining a Buy rating. This follows the successful clearance of a sample size re-estimation for the Phase IIb CORAL study and favorable data from the Human Abuse Potential (HAP) study for their cough treatment candidate, Haduvio. Additionally, Trevi has priced its public offering of 12.5 million shares at $4.00 each, aiming to raise $50 million to support its clinical trials and development efforts. Oppenheimer has also maintained an Outperform rating for Trevi with a $9.00 price target, reflecting confidence in Haduvio’s potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.